Berlin-based startup REMATIQ has secured €5.4 million in seed funding to drive its mission of transforming regulatory compliance in the MedTech industry through artificial intelligence.
The funding round was led by Project A Ventures, with participation from Amino Collective and HelloWorld, alongside prominent angel investors including Spryker Systems co-founder Boris Lokschin and MedTech veteran Timo Fleßner.
REMATIQ has developed the first AI-native platform designed to automate and streamline regulatory compliance for medical technology companies. Regulatory requirements are among the most significant pain points in the sector, consuming over 40% of R&D teams’ time on manual processes.
REMATIQ’s AI engine analyzes global regulations and delivers clear, actionable requirements that integrate seamlessly into product development and quality workflows—cutting documentation efforts by up to 90%.
“Regulatory requirements shouldn’t slow down innovation—they should help accelerate it,”
said David Boutellier, Co-Founder and CEO of REMATIQ.
“With REMATIQ, we turn compliance from a hurdle into a competitive advantage. Our goal is to bring life-saving MedTech solutions—ranging from wound care to advanced imaging systems—to patients faster.”
REMATIQ’s platform is already being used by leading MedTech companies globally, including the B. Braun Group.
“The volume and complexity of international regulations continue to grow,”
said Mandy Blocher, Head of PLM Digitalization & Regulatory Intelligence at B. Braun.
“An AI-based approach like REMATIQ’s targets the exact pressure point: managing ever-expanding regulatory demands efficiently and safely.”
The freshly secured capital will fuel the expansion of REMATIQ’s engineering team, further enhance its proprietary AI technology, and support international growth, with a focus on European and U.S. markets.
Anton Waitz, General Partner at Project A, emphasized the critical nature of the problem REMATIQ is solving:
“Regulatory burdens slow down innovation across the MedTech industry. REMATIQ’s approach enables companies to achieve compliance more efficiently, without compromising safety or quality. Their industry expertise and clear technology vision set them apart.”
Founded in 2023 by David Boutellier and Florian Scherer, REMATIQ was born from the belief that compliance should empower innovation, not hinder it. Their AI-powered platform simplifies global regulations such as MDR and FDA guidelines, translating them into structured, actionable data that integrates into existing systems.
With the new funding and a growing roster of global clients, REMATIQ is poised to redefine how the MedTech industry approaches compliance—making it faster, smarter, and more innovation-friendly.
For more information, visit: www.rematiq.com
